未登录

A

Alan Zwart

georgetown university

H指数:21

被引数:1,785

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-300

OAAI

Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy

在开始前列腺放射治疗之前，在新辅助relugolix后维持患者报告的健康相关生活质量

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-170

OAAI

Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation

FRONTIERS IN ONCOLOGY

IF3.3

2024-11-210

OAAI

Safety and early efficacy of involved-field SBRT for nodal oligo-recurrent prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2024-10-170

OAAI

The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue

FRONTIERS IN ONCOLOGY

IF3.3

2024-08-121

OAAI

Impact of neoadjuvant relugolix on patient-reported sexual function and bother

FRONTIERS IN ONCOLOGY

IF3.3

2024-04-112

OAAI

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2024-03-223

OAAI

Impact of Neoadjuvant Relugolix on Patient-Reported Sexual Function and Bother

JOURNAL OF SEXUAL MEDICINE

IF3.3

2024-02-050

PRE

Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes

FRONTIERS IN ONCOLOGY

IF3.3

2023-11-233

OAAI

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2023-10-174

OAAI

NF-κB Signaling Is Required for XBP1 (Unspliced and Spliced)-Mediated Effects on Antiestrogen Responsiveness and Cell Fate Decisions in Breast Cancer

Nf-κb信号是XBP1 (未剪接和剪接) 介导的乳腺癌抗雌激素反应和细胞命运决定所必需的

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2082

OAAI

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-12-231

OAAI

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-03-256

OAAI

Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer

JOURNAL OF SEXUAL MEDICINE

IF3.3

2022-03-171

PRE

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-01-190

OAAI

PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies

JOURNAL OF PROTEOME RESEARCH

IF3.6

2020-10-1943

OAAI

Local network topology differences between early and late recurrence in ER plus breast cancers

CANCER RESEARCH

IF16.6

2019-02-150

PRE

Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes

CELL DEATH DISCOVERY

IF7

2018-10-1532

OAAI

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities

MOLECULAR AND CELLULAR ENDOCRINOLOGY

IF3.6

2018-08-0122

OAAI

Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling

CANCER RESEARCH

IF16.6

2017-02-150

PRE